Sun et al. [250] discovered that following Berberine (BBR) treatment, the expression of SHH, Ptch1, SMO, Gli1, and c-Myc was down-regulated while the expression of SUFU was up-regulated in HT-29 cells, suggesting that BBR exerts anti-CRC effects by decreasing the Hedgehog signaling pathway activity. The gene discussed is MYC; the disease is colorectal carcinoma.